Product was added to your cart

Our antibodies have been tested on many different tumor and normal tissues.

Our clones have been validated by pathologists from routine diagnostic laboratories.

ONCOdianova is an antibody manfucaturing network linking antibody development to
histopathological validation.

Explore the new anti-TIGIT clone TG2 now with higher staining intensity.

Explore TG2

TEST OUR
ANTIBODIES

CD112R antibody

CD112R

The unique clone R12 is ideally suited for multiplexed IHC studies of CD112R expression in human tissue specimen.

TIGIT antibody

TIGIT

Clone TG1 has been validated on large quantities of tumor tissues and beta-tested by different labs for IHC-FFPE. The new clone TG2 shows higher staining intensity.

FOXP3 antibody

FOXP3

The new clone FX3 has been characterized on hundreds of tissues and validated for multiplex fluorescence IHC.

CD8

Clone TC8 displays highest signal-to-noise contrast and has been validated for detection of CD8+ TILs in multiplex assays.

CD73

Clone KK3 is highly efficient in detection of CD73-adenosine in normal and tumor FFPE tissue.

CALRmut

Unique antibody for detection of all different types of CALRETICULIN mutations in Myeloproliferative Neoplasms.

anti-PSA antibody

PSA

Clone HAM18 has been tested on >20.000 tissues and is the best characterized anti-PSA antibody.

p16

Clone JAP16 is outstanding and superior to competitors as proven by beta-tests from different labs.

more antibodies

We are always happy to discuss your needs!

Contact Us

LOOK
WHAT WE DO

ONCOdianova is an antibody manufacturing network. The purpose is to manufacture excellent antibodies with optimized signal-to-noise ratio. Such optimized antibodies are especially needed in multicolor fluorescence based immunohistochemistry if many different antibodies are simultaneously analyzed. The mission of ONCOdianova is to develop a portfolio of “best in class antibodies” for proteins that are potentially relevant for triggering treatment decisions or for diagnostic pathology.

Develop

Our idea is to integrate immunohistochemistry as early as possible in the hybridoma screening procedure and thereby expand the classical ELISA screen by histopathological expertise at an early stage of FFPE antibody development.

Validate

We use our strong network for histopathological validation of new targets in human tissues. This expands our expertise to develop new test systems for novel targets. For cancer immunology targets we put a focus on tumor infiltrating lymphocytes.

Improve

Multiplex Assay technology develops fast and depends on the availability of reliable antibody reagents. Our vision is to provide the best cancer immunology marker antibodies for combined use to improve the understanding of patient subpopulations.

Partner

Our objective is to potentially develop multiple clones for the same target by approaching one target at diverse immunogenic sites. We are able to reference mapped epitopes and open for beta testing opportunities with pharmaceutical partners.

GET IN TOUCH

We are keen to learn from our clients and actively respond to the aims and interests of our audience. If you think we can do even more, we are always happy to discuss your needs.

Whether you want to find out more information, give us feedback or just ask us a question, please contact us via the contact details or using the online form to the right.

OUR PAYMENT METHODES

Paypal Plus

Prebilling

Oeleckerring 11-13, 22419 Hamburg, Germany

+49 172 44 35 028

info@oncodianova.com
Follow us on Facebook


Mandatory Fields*

Menu
ONCOdianova is a network of experts for the development of excellent antibodies (best-in-class antibodies) for tissue-based detection of tumor markers. The focus is on new biomarkers for tumor immunology checkpoints, as they may be of diagnostic and prognostic significance in the future. ONCOdianova aims to develop antibodies with an optimized signal-to-noise ratio for use in multicolored fluorescence-based IHC (Multiplex immunohistochemistry). The following antibody highlights from ONCOdianova have already developed relevance for clinical histopathology: 1. TIGIT is one of the most important checkpoint markers for the development of new immunotherapies against cancer. With antibody clone TG1, TIGIT could for the first time be detected immunohistochemically in tumor tissue. 2. PVRIG / CD112R plays an important role in the development of effective combination therapies with PD1 and TIGIT. The IHC detection of PVRIG in tumor tissues so far is only possible with clone R12. 3. Antibody clone CAL2 is used for the detection of all types of Calreticulin mutations in myeloproliferative neoplasms (MPN) and reliably differentiates CALRmutated ET and PMF from PV. Our strong feedback from laboratories applying the new ONCOdianova antibodies against CD112R, TIGIT and CALRmut shows that they are perceived as innovative tools for immunohistochemistry, because they allow new approaches for tissue based studies of important biomarkers.